AUTL Stock — Autolus Therapeutics plc: Cash, EV, Pipeline

What they do

We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.28

Market cap

$340.7M

Cash

$201.6M

Enterprise value

$139.1M

Balance sheet

Cash	$201.6M
Debt	$0.0M
Net cash	$201.6M
Enterprise value	$139.1M
Basic shares	266.2M shares
Fully diluted shares	314.1M shares
Fully diluted market cap	$402.0M
Cash per share	$0.76
Quarterly burn	$25.1M
Cash runway	8.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

266.2M

Pre-funded warrants

0.0M

Options

37.4M

RSUs

4.3M

Warrants

3.3M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

3.0M

FDSO

314.1M

Cap table as of 2026-06-30.

Price history

Loading AUTL daily closes…

Loading price history…

Next catalyst

obe-cel · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	obe-cel CARLYSLE Phase 1 in severe refractory SLE	Phase 1	severe refractory SLE	Q4 2026
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	obe-cel BOBCAT Phase 1 in progressive MS	Phase 1	progressive MS	Q1 2027
GUIDEDDec 1-31 in 13 mo	obe-cel CATULUS Phase 2 in pediatric relapsed/refractory B-ALL	Phase 2	pediatric relapsed/refractory B-ALL	end of 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Obecabtagene autoleucel

Approved · Active Modality: CAR T cell therapy

Aliases AUCATZYL, obe-cel

Target CD19

Partnerships BioNTech License and Option Agreement: $40M upfront obe-cel revenue interest; company pays low single-digit % of net sales (up to mid-single digit for up to $100M milestones); Blackstone Collaboration: $50M upfront + 2x$35M development payments + $30M on FDA approval (all received); UCLB exclusive license (milestones including £6.0M EC approval milestone paid Q3 2025); Cardinal Health 105 commercial distribution partner (U.S.); AGC lentiviral vector manufacturing agreement (EUR 25M minimum purchase commitment)

Indications

Relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) (Approved)
Pediatric r/r B-ALL (CATULUS) (Phase 2)
Systemic lupus erythematosus (CARLYSLE) (Phase 1)
Lupus nephritis (LUMINA) (Phase 2)
Progressive multiple sclerosis (BOBCAT) (Phase 1)

Catalysts

— end of 2027
— Q4 2026
— 2028

Status note Fast off-rate CD19 CAR T. FDA BLA approved Nov 8, 2024 for adult (18+) r/r B-ALL; first U.S. sale Jan 2025; European Commission marketing approval Jul 18, 2025 (adult 26+ r/r B-ALL). Filing cites a ~$8M restructuring/realignment program in 2025-2026.

AUTO8

Phase 1 · Active Modality: CAR T cell therapy

Target CD19 (dual-targeting)

Indications

Light-chain amyloidosis (ALARIC) (Phase 1)

Catalysts

— end of 2026

Status note Dual-targeting CAR (second antigen not stated in the excerpts); Phase 1 ALARIC trial ongoing.

AUTO1/22

Stage not disclosed · Active Modality: CAR T cell therapy

Target CD19 (dual-targeting)

Status note Described in the 10-K fallback as a clinical-stage hematological cancer candidate using fast off-rate CD19 and dual-targeting CAR technology; no trial detail in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	4,447,910	no change	0.15%	2026-08-14
DAFNA Capital	179,316	no change	0.05%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AUTL — Autolus Therapeutics plc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

AUTL — Autolus Therapeutics plc